Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Oncogene volume 28, pages S24–S31 (2009)Cite this article

Abstract

The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5′ triphosphate-binding site. Somatic activating mutations of the EGFR gene, increased gene copy number and certain clinical and pathological features have been associated with dramatic tumor responses and favorable clinical outcomes with these agents in patients with non-small-cell lung cancer (NSCLC). The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene. Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed ‘classical’ mutations. The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes. Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease. The point mutation T790M accounts for about one half of these cases of acquired resistance. Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494–6501.

    Article  CAS  Google Scholar 

  • Bazley LA, Gullick WJ . (2005). The epidermal growth factor receptor family. Endocr Relat Cancer 12 (Suppl 1): S17–S27.

    Article  CAS  Google Scholar 

  • Bianco R, Gaofalo S, Rosa R, Damiano V, Gelardi T, Daniele G et al. (2008). Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98: 923–930.

    Article  CAS  Google Scholar 

  • Bonomi PD, Buckingham L, Coon J . (2007). Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13 (15 Suppl): 4606s–4612s.

    Article  CAS  Google Scholar 

  • Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97: 643–655.

    Article  CAS  Google Scholar 

  • Carey KJ, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S et al. (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163–8171.

    Article  CAS  Google Scholar 

  • Ciardello F, Tortora G . (2008). EGFR antagonists in cancer treatment. N Engl J Med 358: 1160–1174.

    Article  Google Scholar 

  • Cortez-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A et al. (2005). Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081–1086.

    Article  Google Scholar 

  • Douillard JY, Hirsch V, Mok TS, Socinski MA, Watkins C, Lowe E et al. (2008). Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) (abstract). J Clin Oncol 26 (Suppl): abstract no. 8001.

    Article  Google Scholar 

  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900–5909.

    Article  CAS  Google Scholar 

  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T et al. (2008). PF00299804, an irreversible pan ErbB inhibitor, is effective in lung cancer models with EGFR and HER2 mutations that are resistant to gefitinib. Cancer Res 67: 11924–11932.

    Article  Google Scholar 

  • Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Duillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237–2246.

    Article  CAS  Google Scholar 

  • Gazdar AF, Minna JD . (2005). Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med 2: e377.

    Article  Google Scholar 

  • Gazdar AF, Minna JD . (2008). Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res 1: 156–160.

    Article  CAS  Google Scholar 

  • Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2: e313.

    Article  Google Scholar 

  • Han SE, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS et al. (2005). Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493–2501.

    Article  CAS  Google Scholar 

  • Hirsch FR, Franklin WA, McCoy J . (2006). Predicting clinical benefit from EGFR TKIs: not all EGFR mutations are equal (abstract). J Clin Oncol 24: 382s.

    Google Scholar 

  • Ikeda K, Nomori H, Takeshi M, Sasaki K, Kobayashi T . (2008). Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 85: 1430–1432.

    Article  Google Scholar 

  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA et al. (2006). Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908–3914.

    Article  CAS  Google Scholar 

  • Jänne PA, Johnson BE . (2006). Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12 (14 Suppl): 4416s–4420s.

    Article  Google Scholar 

  • Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD . (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968–8974.

    Article  CAS  Google Scholar 

  • Kancha RK, von Bubnoff N, Peschel C, Duyster J . (2009). Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 15: 460–467.

    Article  CAS  Google Scholar 

  • Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352: 786–792.

    Article  CAS  Google Scholar 

  • Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T . (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919–8923.

    Article  CAS  Google Scholar 

  • Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764–5769.

    Article  CAS  Google Scholar 

  • Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290: 2149–2158.

    Article  CAS  Google Scholar 

  • Kumar A, Petri ET, Halmos B, Boggon TJ . (2008). Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742–1751.

    Article  CAS  Google Scholar 

  • Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGFR receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.

    Article  CAS  Google Scholar 

  • Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702–4711.

    Article  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.

    Article  CAS  Google Scholar 

  • Maheswaran S, Sequist LV, Nagrath S, Ulkus L . (2008). Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med 359: 1–12.

    Article  Google Scholar 

  • Miller VA, Kris MG . (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103–1109.

    Article  CAS  Google Scholar 

  • Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S et al. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513–2520.

    Article  CAS  Google Scholar 

  • Mok T, Wu Y-L, Thongprasert S, Yang C-H, Chu D, Saijo N et al. (2008). Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS) (abstract). Ann Oncol 19 (Suppl 8): LBA2.

    Google Scholar 

  • Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.

    Article  CAS  Google Scholar 

  • Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311.

    Article  CAS  Google Scholar 

  • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005a). Acquired resistance of lung adenocarcinomas to gefitinib and erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.

    Article  Google Scholar 

  • Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005b). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.

    Article  Google Scholar 

  • Paz-Ares L, Sanchez JM, Garcia-Velasco B . (2006). A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) (abstract). J Clin Oncol 24 (Suppl): 369s.

    Google Scholar 

  • Perez-Soler R, Chachoua A, Hammond LA, Rowinski EK, Huberman M, Karp D et al. (2004). Determinants of tumor response and survival and erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22: 3238–3247.

    Article  CAS  Google Scholar 

  • Politi K, Zakowski MF, Fan PD, Schoenfeld EA, Pao W, Varmus HE . (2006). Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancer respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496–1510.

    Article  CAS  Google Scholar 

  • Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839–844.

    Article  CAS  Google Scholar 

  • Sharma SV, Bell DW, Settleman J, Haber DA . (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.

    Article  CAS  Google Scholar 

  • Shepherd F, Tsao MS . (2006). Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24: 1219–1220.

    Article  Google Scholar 

  • Shepherd FA, Pereria J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. (2005). Erlotinib in previously treated non-small cell lung cancer. N Eng J Med 353: 123–132.

    Article  CAS  Google Scholar 

  • Shigematsu H, Gazdar AF . (2006). Somatic mutations of epidermal growth factor receptor-signaling pathway in lung cancers. Int J Cancer 118: 257–262.

    Article  CAS  Google Scholar 

  • Takano T, Ohe Y, Sakamotto H, Tsuta K, Matsuno Y, Tateishi U et al. (2005). Epidermal growth factor receptor gene mutations and increased copy number predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829–6837.

    Article  CAS  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multi-centre study (Iressa survival evaluation in lung cancer). Lancet 366: 1527–1537.

    Article  CAS  Google Scholar 

  • Wong KK . (2007). HKI-272 in non-small cell lung cancer. Clin Cancer Res 13 (15 Part 2): S4593–S4596.

    Article  Google Scholar 

  • Yang C-H, Yu C-J, Shih J-Y, Cheng Y-C . (2008). Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib therapy. J Clin Oncol 26: 2745–2753.

    Article  CAS  Google Scholar 

  • Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK et al. (2008). The T790 mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070–2075.

    Article  CAS  Google Scholar 

  • Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM . (2009). Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076–2084.

    Article  CAS  Google Scholar 

  • Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J . (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137–1149.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I thank Johnathan C Maher, PhD of BlueSpark Healthcare Communications for medical and editorial assistance with this article. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals Inc. Supported by grant P50CA70907 from the Specialized Programme for Research Excellence in Lung Cancer from the National Cancer Institute, Bethesda, MD, USA.

Author information

Authors and Affiliations

  1. Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    A F Gazdar

Authors
  1. A F Gazdar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A F Gazdar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gazdar, A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 (Suppl 1), S24–S31 (2009). https://doi.org/10.1038/onc.2009.198

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.198

Keywords

This article is cited by

Search

Advanced search

Quick links